Grants per year
Grants
Search results
-
Finished
Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok
Covance Inc., Bayer HealthCare Pharmaceuticals, Inc.
2/22/18 → 6/1/19
Project: Research project
-
Prot #1315.2: An Open-Label, Phase I/II Trial To Determine The Maximum Tolerated Dose And Investigate Safety, Pharmacokinetics And Efficacy Of BI 836858 In Combination With Decitabine In Patients With Acute Myeloid Leukemia
Boehringer Ingelheim Pharmaceuticals, Inc.
2/13/17 → 2/13/20
Project: Research project
-
Prot #AG881-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/o
Novella Clinical, LLC, Agios Pharmaceuticals, Inc.
8/31/15 → 8/31/18
Project: Research project
-
MLN8237, an Aurora A kinase inhibitor, for treatment of myeloid malignancies
Altman, J. K., Crispino, J. D., Giles, F. J., Stein, B. L. & Wen, Q.
10/1/14 → 8/31/19
Project: Research project
-
Prot #AG120-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
INC Research, LLC, Agios Pharmaceuticals, Inc.
7/31/14 → 7/31/20
Project: Research project
-
Prot #CA180406: Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
ICON Clinical Research, LLC, Bristol-Myers Squibb Company
3/10/14 → 3/10/17
Project: Research project
-
Prot #MEI-005: A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
SCRI Development Innovations, LLC, MEI Pharma, Inc.
3/7/14 → 3/7/17
Project: Research project
-
Improving Outcomes of Older and Medically Infirm Patients with AML
Fred Hutchinson Cancer Research Center, Patient-Centered Outcomes Research Institute
1/1/14 → 6/30/18
Project: Research project
-
Prot #2215-CL-0101: A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc.
9/23/13 → 9/23/16
Project: Research project
-
-
Prot #B1371003: A Phase 1B Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose ARA-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myel
ICON Clinical Research, LLC, Pfizer Inc.
10/17/12 → 10/17/18
Project: Research project
-
Prot# NU MSK 11H01: Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Altman, J. K., Frankfurt, O., Stein, B. L. & Winter, J. N.
Memorial Sloan-Kettering Cancer Center
6/15/12 → 6/15/18
Project: Research project
-
Prot# 2689-CL-2004: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc.
5/30/12 → 5/30/18
Project: Research project
-
Prot# C15003: An Open Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Millennium Pharmaceuticals, Inc
6/17/11 → 6/17/14
Project: Research project
-
Prot# CYC682-12 (A2): A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
6/15/11 → 6/15/17
Project: Research project